Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT03248570 Not yet recruiting - Clinical trials for Metastatic Prostate Cancer

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Start date: October 1, 2017
Phase: Phase 2
Study type: Interventional

This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.

NCT ID: NCT03247010 Recruiting - Clinical trials for Castration-resistant Prostate Cancer

Bone Marrow Suppression and Recovery During Radionuclide Treatment

Start date: June 20, 2017
Phase: N/A
Study type: Observational

Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant prostate cancer and bone metastases. Therapy is administered intravenously every 4 weeks for up to 6 cycles. More than 20 % of patients treated at Rigshospitalet develop bone marrow suppression as a side effect to Radium therapy, which delays or excludes the patient from further oncological therapy. Especially thrombocytopenia is a frequent side-effect and can be long lasting. The aim of the study is to examine whether biomarkers of bone marrow recovery (immature platelets, platelet volume, reticulocytes, red cell distribution width) can predict development of hematological toxicity during Radium therapy. Furthermore, to investigate whether these biomarkers can predict recovery from toxicity in patients who develop bone marrow suppression during therapy.

NCT ID: NCT03246802 Not yet recruiting - Clinical trials for Recurrent Prostate Cancer

Partial Prostate Salvage High Dose Rate Brachytherapy

SalvageHDR
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.

NCT ID: NCT03246347 Not yet recruiting - Prostate Cancer Clinical Trials

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer. The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated and demonstrates improved efficacy compared to ADT + docetaxel.

NCT ID: NCT03242265 Recruiting - Prostatic Neoplasm Clinical Trials

Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy

ANKA-PCA
Start date: April 4, 2017
Phase: N/A
Study type: Interventional

This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for prostate cancer using prostate biopsy.

NCT ID: NCT03241758 Completed - Prostatic Neoplasms Clinical Trials

Vascular Changes Of Patients Undergoing Laparoscopic Radical Prostatectomy

Start date: November 29, 2011
Phase: N/A
Study type: Observational

A study designed to evaluate vascular changes after radical laparoscopic prostatectomy using Doppler ultrasound and the impact of such changes on erectile function and quality of life of patients. The baseline study will be compared with the study one year after surgery.

NCT ID: NCT03241537 Recruiting - Prostate Neoplasm Clinical Trials

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

Start date: January 15, 2016
Phase: N/A
Study type: Interventional

In local advanced prostate cancer patients with clinically positive metastatic regional lymph node, the optimal treatment is still unanswered. For these patients, radiotherapy combined with hormonal therapy or hormonal therapy alone are recommended. Recently, the reports from NCCB and SEER data showed that radiotherapy combined with hormonal therapy have better survivals than hormonal therapy alone. This randomized phase III trial compare hormonal therapy alone with combined hormone with radiotherapy in clinically pelvic lymph node metastatic prostate cancer.

NCT ID: NCT03238170 Recruiting - Clinical trials for Cancer of the PROSTATE

MR-simulation in Radiotherapy for Prostate Cancer

FIMRA-P
Start date: March 1, 2017
Phase: N/A
Study type: Interventional

To assess the feasibility of acquiring an MR scan in the radiotherapy treatment position as part of the patient's radiotherapy pathway and incorporating the data into our radiotherapy planning systems, so that it can be potentially used to reduce healthy tissue exposure to radiation. Subsequently, the protocols and procedures established can be used to put the technique into routine clinical practice.

NCT ID: NCT03238066 Recruiting - Prostate Cancer Clinical Trials

Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy

Prostata-BT-HT
Start date: April 2015
Phase: N/A
Study type: Interventional

Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent prostate carcinoma following external beam radiation therapy.

NCT ID: NCT03237702 Recruiting - Cancer Screening Clinical Trials

Decipher Lethal Prostate Cancer Biology - Urine Metabolomics

Start date: July 31, 2017
Phase: Early Phase 1
Study type: Interventional

Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer. In the meantime, with these new markers we may substantially reduce overtreatment of insignificant PC.